Despite major advances, heart failure (HF), until now categorised as HF with preserved/altered ejection fraction, acute/chronic, still has a very high mortality. Our consortium, led by the CARTAGE HIF, has international leadership through several major research programmes (EUFP7, clinical trials, ANR, PHRC) and aims to combat this scourge (FIGHT-HF: "Fighting Heart Failure") through a strategic approach including i) a better understanding of the etiopathogenic mechanisms, ii) bio-profiling by omics and imaging, iii) taking into account co-morbidities, iv) a holistic approach With the ultimate goal of changing the categorisation of CI and improving the prognosis of CI, we aim to :
1. Identify and validate new bio-targets in our areas of expertise (fibrosis, large arteries, coagulation, TREM-1)
2. validate omics biomarkers, telomere dynamics and MRI imaging to obtain an individual bio-profile and guide treatment
3. Develop treatment strategies taking into account the most frequent comorbidities (hypertension, diabetes, renal failure, frailty in the elderly), the need for remote monitoring and patient-perceived health and cost-effectiveness analyses.
monitoring as well as the patient's perceived health and cost-effectiveness analyses
4. Implement a complex knowledge network approach using the generated data to generate new
knowledge network approach to generate new hypotheses
5. Develop and exploit new technologies (drugs, blood biomarkers and
MRI) with our 3 regional industrial partners, including 2 start-up spin-offs from our
academic laboratories.
Interactions between different workpackages
